Federated Hermes Inc. Boosts Holdings in Vericel Co. (NASDAQ:VCEL)

Federated Hermes Inc. grew its position in shares of Vericel Co. (NASDAQ:VCEL - Free Report) by 25.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,122,373 shares of the biotechnology company's stock after acquiring an additional 227,675 shares during the period. Federated Hermes Inc. owned about 2.27% of Vericel worth $61,630,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of VCEL. Arcadia Investment Management Corp MI bought a new stake in Vericel in the fourth quarter valued at $48,000. Smartleaf Asset Management LLC increased its position in shares of Vericel by 511.1% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,265 shares of the biotechnology company's stock valued at $70,000 after buying an additional 1,058 shares during the period. Meeder Asset Management Inc. raised its stake in Vericel by 8.4% in the fourth quarter. Meeder Asset Management Inc. now owns 2,357 shares of the biotechnology company's stock worth $129,000 after buying an additional 183 shares in the last quarter. Geneos Wealth Management Inc. lifted its holdings in Vericel by 826.6% in the fourth quarter. Geneos Wealth Management Inc. now owns 2,511 shares of the biotechnology company's stock worth $138,000 after buying an additional 2,240 shares during the period. Finally, KBC Group NV boosted its position in Vericel by 82.5% during the 4th quarter. KBC Group NV now owns 2,707 shares of the biotechnology company's stock valued at $149,000 after acquiring an additional 1,224 shares in the last quarter.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the company. StockNews.com upgraded Vericel from a "sell" rating to a "hold" rating in a research note on Saturday, March 8th. HC Wainwright reissued a "buy" rating and set a $60.00 price objective on shares of Vericel in a research report on Friday, February 28th. Canaccord Genuity Group upped their target price on shares of Vericel from $64.00 to $67.00 and gave the stock a "buy" rating in a research report on Monday, February 3rd. Stephens reissued an "overweight" rating and set a $65.00 price target on shares of Vericel in a research report on Wednesday, January 15th. Finally, Truist Financial cut their price objective on shares of Vericel from $61.00 to $51.00 and set a "buy" rating on the stock in a report on Friday. One analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $60.86.

Remove Ads

Vericel Stock Performance

Shares of NASDAQ:VCEL traded down $0.65 during trading on Friday, reaching $41.25. 601,588 shares of the stock traded hands, compared to its average volume of 389,631. Vericel Co. has a 52-week low of $37.76 and a 52-week high of $63.00. The stock has a market cap of $2.07 billion, a P/E ratio of 687.61 and a beta of 1.61. The stock has a 50-day moving average of $49.21 and a two-hundred day moving average of $51.42.

Insiders Place Their Bets

In other news, CEO Dominick Colangelo sold 24,850 shares of the firm's stock in a transaction dated Thursday, April 10th. The shares were sold at an average price of $41.89, for a total transaction of $1,040,966.50. Following the sale, the chief executive officer now owns 260,354 shares of the company's stock, valued at $10,906,229.06. This trade represents a 8.71 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Jonathan Siegal sold 1,092 shares of the business's stock in a transaction that occurred on Wednesday, February 5th. The shares were sold at an average price of $61.99, for a total transaction of $67,693.08. Following the transaction, the insider now directly owns 1,206 shares of the company's stock, valued at $74,759.94. The trade was a 47.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 58,942 shares of company stock valued at $2,724,548. Corporate insiders own 5.20% of the company's stock.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.